|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM303682272 |
| 003 |
DE-627 |
| 005 |
20231225113339.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.108313
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1012.xml
|
| 035 |
|
|
|a (DE-627)NLM303682272
|
| 035 |
|
|
|a (NLM)31765833
|
| 035 |
|
|
|a (PII)S1521-6616(19)30533-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Nyambuya, Tawanda Maurice
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus
|b A systematic review and meta-analysis
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.07.2020
|
| 500 |
|
|
|a Date Revised 31.07.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019. Published by Elsevier Inc.
|
| 520 |
|
|
|a BACKGROUND: Chronic immune activation has been described in the development of cardiovascular diseases (CVDs) and in the pathogenesis of type 2 diabetes mellitus (T2D). However, the precise functional role of T-cells remains controversial. We therefore, assessed T-cell activation and cardiovascular risk in T2D
|
| 520 |
|
|
|a METHODS: The protocol was registered with PROSPERO [CRD42018099745]. We searched electronic databases and grey literature for eligible studies. The risk of bias and quality of evidence were assessed and the random-effects model was used in the meta-analysis
|
| 520 |
|
|
|a FINDINGS: Fifteen studies met the inclusion criteria. We report on increased T-cell activation in T2D and nondiabetics with CVD. Comorbidity of T2D and CVD (T2D + CVD) exacerbated T-cell activation. In addition, T2D + CVD comorbidity was associated with an increased CVD risk profile
|
| 520 |
|
|
|a CONCLUSION: This meta-analysis suggests increased T-cell activation in T2D and nondiabetics with CVD. Moreover, an increased cardiovascular risk in patients with T2D which is exacerbated in T2D and CVD comorbidity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Meta-Analysis
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Systematic Review
|
| 650 |
|
4 |
|a Cardiovascular diseases
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a T-cell activation
|
| 650 |
|
4 |
|a Type 2 diabetes mellitus
|
| 700 |
1 |
|
|a Dludla, Phiwayinkosi Vusi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mxinwa, Vuyolwethu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nkambule, Bongani Brian
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 210(2020) vom: 01. Jan., Seite 108313
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:210
|g year:2020
|g day:01
|g month:01
|g pages:108313
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.108313
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 210
|j 2020
|b 01
|c 01
|h 108313
|